Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07570966 · Novartis Pharmaceuticals · PHASE1/PHASE2 · withdrawn · last registry update 2026-06-22 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business decision” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ESR1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-23Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Fulvestrant + Pyrotinib (NCT07892274)
- 2026-10-15Also stopped (terminated): Spanish Breast Cancer Research Group, Trastuzumab + Alpelisib (NCT05063786)
- 2026-10-14Also stopped (terminated): UNICANCER, Alpelisib + Ribociclib (NCT05625087)
- 2026-09-25Results posted on the registry: Dartmouth-Hitchcock Medical Center, 17B-estradiol + Letrozole (NCT02188745)
- 2026-09-24Results posted on the registry: Tvardi Therapeutics, Incorporated, TTI-101 + Palbociclib (NCT05384119)
- 2026-09-24Also stopped (terminated): Tvardi Therapeutics, Incorporated, TTI-101 + Palbociclib (NCT05384119)
- 2026-09-03Phase 3 first posted: SWOG Cancer Research Network, NSAI + CDK4/6i + NSAI + CDK4/6i + Capivasertib (NCT07802626)
- 2026-08-25Phase 3 first posted: Chengdu JOYO pharma Co., Ltd., JYP0035 plus Fulvestrant + JYP0035 placebo plus Fulvestrant (NCT07784036)
- 2026-08-19Also stopped (terminated): Boundless Bio, Inc., BBI-940 + Fulvestrant (NCT07408089)
- 2026-08-07Results posted on the registry: Priscilla McAuliffe, Tamoxifen + Anastrozole (NCT02206984)
- 2026-07-21Results posted on the registry: Context Therapeutics Inc., Elacestrant + Onapristone (NCT05618613)
- 2026-07-21Also stopped (terminated): Context Therapeutics Inc., Elacestrant + Onapristone (NCT05618613)
- 2026-07-10Results posted on the registry: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-10Also stopped (terminated): Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-06-25Results posted on the registry: Novartis Pharmaceuticals, Alpelisib + Fulvestrant (NCT05631795)
- 2026-06-25Also stopped (terminated): SOLTI Breast Cancer Research Group, Ribociclib + Letrozole OR Fulvestrant + Palbociclib + Letrozole OR Fulvestrant (NCT05207709)
- 2026-05-14Results posted on the registry: EQRx, Inc., Lerociclib + Letrozole or Fulvestrant (NCT05085002)
- 2026-05-14Also stopped (terminated): EQRx, Inc., Lerociclib + Letrozole or Fulvestrant (NCT05085002)
- 2026-03-31Also stopped (terminated): Criterium, Inc., Abemaciclib + Elacestrant (NCT04791384)
- 2026-03-05Results posted on the registry: Mayo Clinic, Therapeutic Estradiol (NCT03941730)
- 2026-03-03Results posted on the registry: National Cancer Institute (NCI), Binimetinib + Fulvestrant (NCT05554354)
- 2026-03-03Also stopped (terminated): National Cancer Institute (NCI), Binimetinib + Fulvestrant (NCT05554354)
- 2026-02-24Results posted on the registry: Mayo Clinic, Anastrozole + Denifanstat (NCT03179904)
- 2026-02-24Also stopped (terminated): Sanofi, Amcenestrant + Fulvestrant (NCT04059484)
- 2026-02-24Results posted on the registry: City of Hope Medical Center, Fulvestrant + Letrozole (NCT02778685)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision